July 9th, 2026
There is a large body of evidence in animal studies to show that treatment with dasatinib and quercetin clears a fraction of the lingering senescent cells present in tissues throughout the body to restore more youthful function to many different organs and systems. Today's open access paper, focused on kidney rejuvenation via removal of senescent cells, is yet another to add to the scores of existing studies. Dasatinib is a generic chemotherapeutic drug, while quercetin is a plant flavonol; both cost little. Dasatinib can be readily obtained these days via anti-aging clinical practices, offshore pharmacies, and the other usual approaches to access low cost prescription drugs. Quercetin can be found in any supplement store.
Sadly, exactly because dasatinib and quercetin are cheap compounds, there is very little incentive for anyone to fund the sizable expense of running large clinical trials to first establish optimal dosing, and secondly confirm that this treatment is as good for aged humans as it is for aged mice. Those trials that have taken place were funded by academic institutions, were small, exploratory, and the results were promising. Only larger trials can move from promising to "yes, this works," however. Meanwhile, any older person willing to put in the effort can run their own study of one, and see how a range of biomarkers look before and after treatment. The human trials suggest that side-effects for a short course of treatment are minimal compared to potential benefits.
